Royalty Pharma Preps Proxy for Key Transaction

TL;DR

Royalty Pharma filing proxy materials for a big deal vote.

AI Summary

Royalty Pharma plc filed a DEFA14A, indicating it is soliciting materials prior to furnishing a definitive proxy statement for a proposed transaction. The filing, dated January 17, 2025, is from the company itself and concerns communications made before the distribution of official proxy materials.

Why It Matters

This filing signals an upcoming shareholder vote on a significant corporate action, which could impact the company's future strategy and financial performance.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not inherently indicate increased risk for the company.

Key Players & Entities

• Royalty Pharma plc (company) — Registrant
• 0000950103-25-000651 (filing_id) — Accession Number
• 20250117 (date) — Filing Date

FAQ

Key Financial Figures

• $2 billion — ation strategy, including the potential $2 billion of share repurchases in 2025, and our a

Filing Documents

• dp223612_defa14a.htm (DEFA14A) — 24KB
• image_001.jpg (GRAPHIC) — 35KB
• 0000950103-25-000651.txt ( ) — 73KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Section 240.14a-12 Royalty Pharma plc (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 This Schedule 14A relates solely to preliminary communications made prior to furnishing security holders of Royalty Pharma plc (the "Company") with a definitive proxy statement related to a proposed transaction in which the Company's subsidiary, Royalty Pharma Holdings Ltd. ("RPH"), entered into a Membership Interest Purchase Agreement with Royalty Pharma, LLC ("RP LLC"), a Delaware limited liability company, RP Management, LLC, a Delaware limited liability company, and the sellers named therein (the "Sellers"), pursuant to which, upon the terms and subject to the conditions set forth therein, RPH will acquire all of the equity interests of RP LLC from the Sellers. This Schedule 14A consists of an internal communication delivered by Pablo Legorreta to employees of Royalty Pharma on January 17, 2025 relating to an investor conference with JPMorgan. * * * Dear Colleagues, We had the opportunity to participate in the J.P. Morgan Conference this week, where we held many positive meetings with investors and business partners. I am thrilled to share some of the highlights with you. On the investor relations side, we met with approximately 40 investors across 30 unique institutions. Investors were excited about the internalization of RP Management, and its announcement was a focal point of our conversations. We also discussed our capital allocation strategy, including the potential $2 billion of share repurchases in 2025, and our attractive pipeline of late-stage products. The positive feedback we received at the conference is a testament to the confidence our investors have in our strategy and approach to capital allocation. In addition to these investor meetings, a large group of our colleagues also attended the conference for business development purposes. They met with more than one hundred existing and prospective business partners to discuss potential funding transactions. We are off to a strong start in 2025! Thank you to everyone for the monumental effort to achieve the announcement of the internalization transaction ahead of the J.P. Morgan Conference. I know that many of you worked around the clock, giving up a meaningful portion of your holidays to make this happen. In particular, I wanted to acknowledge the contributions made by our legal, accounting, finance and investor relations teams. The hard work and commitment demonstrated by these teams were instrumental in reaching this milestone. Your unwavering dedication is truly appreciated. I look forward to continuing this journey together and achieving even greater success in the year ahead. Best, /s/ Pablo Legorreta Pablo Legorreta Founder & Chief Executive Officer Cautionary Note Regarding Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth, and plans for capital deployment, plus the benefits of the Transaction, including cash savings, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of si

View Full Filing

View this DEFA14A filing on SEC EDGAR